Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)

•EGFR-TKI osimertinib inhibits EGFR-TKI sensitizing and T790 M resistance mutations.•Assessing appropriate EGFR-TKI (monotherapy or in combination) sequencing is needed.•The role of sequencing for maximal benefit in EGFRm advanced NSCLC is explored here. Non-small cell lung cancer (NSCLC) is the mos...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Lung cancer (Amsterdam, Netherlands) Netherlands), 2019-11, Vol.137, p.113-122
Hauptverfasser:	Gelatti, Ana C.Z., Drilon, Alexander, Santini, Fernando C.
Format:	Artikel
Sprache:	eng
Schlagworte:	Epidermal growth factor receptor Exon 19 deletion Exon 21 mutation Non-small cell lung cancer Sequencing Tyrosine kinase inhibitor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!